Retina International

Retina International supports this International Universal Health Coverage Day and urges decision makers around the world to protect people from financial hardship when accessing health services  #HealthForAll #UniversalHealthCoverage #UHCDay #equity #UHC

The Retina International World Congress 2024 (RIWC24), hosted by Fighting Blindness and supported by Retina International taking home the top prize in the Educational Meeting of the Year category at the 2024 Irish Healthcare Awards marks a monumental achievement. Bringing together leading retinal scientists, clinicians, advocates, and patient representatives from across the globe, RIWC24 was more than just an event—it fostered critical collaboration and innovation in the field of retinal research. Such milestones remind us of the power of collective effort, innovation, and the relentless pursuit of a shared vision. Congratulations to the incredible team behind RIWC24, and to everyone who played a part in making this event a success. Thanks also to industry partners for supporting this event. #riwc2024 #retina #conference #visionresearch #eyeresearch #ppi #patient

🎉 We are delighted to share the news that the Retina International World Congress (RIWC24), hosted by Fighting Blindness, won the top prize in the Educational Meeting of the Year category at the 2024 Irish Healthcare Awards! 🏆   The Irish Healthcare Awards are Ireland’s leading and most prestigious medical Awards. Created by Irish Medical Times, the Awards are now in their 23rd year and recognise innovation and excellence across the Irish healthcare sector.   The RIWC24 brought together top retinal scientists, clinicians, advocacy leaders, and patient representatives, fostering collaboration and innovation in retinal research.   We worked closely with our fantastic colleagues at Retina International (RI) to bring this event to Dublin and we were delighted to meet RI members from all over the world!   Find more at the link below: https://lnkd.in/dVtVzBes Huge thanks to all involved who made this event an incredible success 👏   #IMTIHA24 #Awards #Announcement #Congress #Healthcare #IrishHealthcare #IrishHealthcareAwards #RetinaInternational #RetinaInternationalWorldCongress #RIWC4 #SightLoss #PublicEngagement #Networking #Community #Education #Research #InheritedRetinalDisease #AgeRelatedMacularDegeneration #FundingResearch #IrishCharity #FightingBlindness

I was honored to participate in a panel discussion at the European conference of ISPOR—The Professional Society for Health Economics and Outcomes Research focusing on the topic of Budget Impact Analysis (BIA) for gene therapies. Thank you to the moderator and my fellow panelists for their invaluable insights Grace Hampson, Scott Ramsey and special thanks to David Sanchez (Retina International) who started with sharing his personal experience when living with an inherited retinal disease. Here are some key takeaways from our discussion:   - There is a growing pipeline of technologies focused on prevention and disease interception with the potential to deliver long-term benefits. However, current BIA methods often emphasize short-term direct healthcare costs, potentially overlooking the broader societal benefits and long-term savings that gene therapies can provide. Eventually this could lead to suboptimal resource allocation and inadequate assessment on implications when used in decision-making.   - While it can be argued that BIA can be used for budget planning, this is different when BIA is used to inform reimbursement decisions. Focusing on short term risks from a very narrow perspective in BIA can lead to inadequate assessment of affordability risks and misinformed decision-making.   - If BIA is applied to assess affordability and inform reimbursement decision-making, we must modernize our methodologies to enhance the scope and accuracy of the assessment.   - It is essential for policymakers and Health Technology Assessment (HTA) bodies to adopt a holistic and long-term perspective in BIA. This includes considering a more extensive range of costs beyond healthcare costs and include the impact of managed entry agreements. By advancing these methodologies, we can better capture the impact of innovative and preventive healthcare technologies, ultimately improving patient access.   #HealthcareInnovation #ISPOR #EconomicEvaluation #BIA #BudgetImpactAnalysis #GeneTherapy

Our Head of Research Dr Nabin Paudel, PhD presenting poster at #ISPOREurope.